The global market for continuous glucose monitoring devices is set to more than double by 2032, as advancements in wearable sensors and digital health tools elevate diabetes management to new levels.
Analysts expect the market for continuous glucose monitoring devices to keep expanding as diabetes rates rise and more care moves towards connected, real-time tracking. One QYResearch report, the basis for this article, says the market was worth about $10.03 billion in 2025 and could climb to $25.73 billion by 2032, driven by a 14.6% compound annual growth rate. Other industry forecasts point to a similar direction, with Grand View Research projecting the broader CGM devices market to reach $41.41 billion by 2033, while alternative estimates place the sector on a slower but still steady growth path.
CGM systems have moved well beyond simple blood sugar checks. They use wearable sensors, wireless links and software to provide continuous readings, trend data and alerts, helping patients and clinicians see glucose swings that finger-prick tests can miss. Grand View Research said the category is being supported by the spread of mobile applications and digital therapeutics, while another market study described CGM as increasingly central to insulin-treated diabetes care and remote monitoring programmes.
The main growth driver remains the global burden of diabetes, but technology is widening the addressable market. Research from Grand View Research showed sensors accounted for 62.8% of revenue in 2025, while Bluetooth connectivity held 57.3%, underlining the importance of compact hardware and wireless data transfer. Reports from other firms also point to growing use in home care, remote patient monitoring and metabolic health, as manufacturers push smaller, longer-lasting sensors and more smartphone-friendly products.
North America remains the largest market, helped by higher diagnosis rates, stronger reimbursement and quicker adoption of connected devices. Abbott, Dexcom, Medtronic, Senseonics and i-Sens remain among the best-known competitors, but the field is becoming more crowded as companies compete on accuracy, comfort, wear time and integration with insulin delivery systems. Industry reports also suggest that artificial intelligence, subscription-based sensor replacement and tighter data security will shape the next phase of competition.
Disclaimer: This content is for informational purposes only and is not intended to be a substitute for professional medical judgment, advice, diagnosis, or treatment.
